Just Answers - Finance

Over the last eight weeks [June, 2006] I've been spending a lot of time reading articles describing the current market conditions...trying to figure if it

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

really affects penny stock investors.

Are we in a bull market...are we wading into a bear market. Or is the recent rally just a dead-cat bounce?

The dead

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

cat bounce refers to a short-term recovery in a declining trend. There's a (relatively) old saying in investing: even a dead cat will bounce if it's droppe

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

from high enough.

No matter how you slice it...I'm not sure it even matters to penny stock investors like you and me.

For example...stocks surged in Jap

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

n this week as reports showed growth in manufacturing and exports. Markets rose across Asia as investors were encouraged by Wednesday's gains on Wall Stree

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

.

Strong earnings reports from two bellwether stocks gave penny stock investors hope that rising interest rates wouldn't kill profits. The recent sell-off

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

said one economist was "just turbulence."

The turbulence, it seems, is continuing on this side of the pond. U.S. stocks traded flat to lower Thursday as

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

he market took a breather as higher oil prices and downbeat economic data curbed Wall Street's momentum. So, what are we to believe, is the market heading

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

p...or heading down?

How does the market look in general terms? As far as stocks are concerned, the S&P index is up just 0.3 percent for the year, the Dow

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

is up 3.4 percent and the NASDAQ is down 2.9 percent. Not sparkling data.

But for penny stock investors, the recent roller coaster ride that many seasoned

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

blue chip investors are reeling over, is just par for the course. We know that a penny stock is often volatile and just as unpredictable.

While a penny st

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

ock may be more vibrant when the market is upbeat, in general, a penny stock marches to its own tune. Why? Few investors venture into the field of penny st

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

cks because they are either unwilling or unable to do the work required to accurately predict what these shares may do.

By their nature, it is nearly impo

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

sible to know what price a penny stock share should be trading at, and conventional financial ratios and industry comparisons are rarely effective measures

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

for realizing a penny stock's value. Large one-day percentage gains and losses are not an uncommon occurrence for penny stock investors.

So really, bull,

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

ear or cat...it's just another day at the computer screen for penny stock investors. The work may be fun...but it's not easy. Of the 14,000 public companie

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

in the U.S., about 3,300 are considered penny stocks that trade on the OTC Bulletin Board operated by the NASDAQ.

Their visibility is low, chances are yo

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

've never heard of their CEO and I doubt they have any institutional following. And while they're highly speculative, the more promising ones have a target

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

d business plans, and solid positions in niche markets. And for now, they're flying under the radar of Wall Street

So what do you do in an unpredictable m

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

rket like the one we're in? Continue applying the same principles you've always used when searching for that untapped penny stock. And enjoy the volatility

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.justanswers.org.ua/article/117349/justanswers-Bear-Market-Bull-Market-or-DeadCat-BounceIt-Matters-Little-to-the-Stalwart-Penny-Stock.html">Bear Market, Bull Market or Dead-Cat Bounce...It Matters Little to the Stalwart Penny Stock</a>

BB link (for phorums):
[url=http://www.justanswers.org.ua/article/117349/justanswers-Bear-Market-Bull-Market-or-DeadCat-BounceIt-Matters-Little-to-the-Stalwart-Penny-Stock.html]Bear Market, Bull Market or Dead-Cat Bounce...It Matters Little to the Stalwart Penny Stock[/url]

Undoubtedly, the most important property in the operation of electrical equipment is electromagnetism. It's the property of attraction and repulsion that enables motors, generators, solenoids, relays and other control equipment to function...

Research shows that the key ingredient for retention lies within the managers ability to understand what employees really want.

Tags

Links

Just Answers - Bear Market, Bull Market or Dead-Cat Bounce...It Matters Little to the Stalwart Penny Stock

Related Articles: